Latest Trials

EudraCT Number: 2004-004557-25 Sponsor Protocol Number: NMS-0100-012 Start Date: 2005-06-03
Sponsor Name: NERVIANO MEDICAL SCIENCE
Full Title: Phase II study of Brostallicin a(PNU- 166196) and Cisplatin (CDDP) in Adult Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)preceded by a dose-escalation component
Medical condition: Use in combination with cisplatin for the treatment of recurrent squamous cell carcinoma of the head and neck
Disease: Version SOC Term Classification Code Term Level
6.1 10024530 HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2004-005215-29 Sponsor Protocol Number: 03-CoFactor Start Date: 2005-06-03
Sponsor Name: ADVENTRX Pharmaceuticals Inc
Full Title: A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU versus Leucovorin and 5-FU in Subjects with Metastatic Colo...
Medical condition: Metastatic Colorectal Carcinoma
Disease: Version SOC Term Classification Code Term Level
7.1 10052358 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: (No results available)
EudraCT Number: 2005-001027-11 Sponsor Protocol Number: AS07/1104-001 Start Date: 2005-06-03
Sponsor Name: University Hospitals Coventry and Warwickshire NHS Trust
Full Title: Diabetes in the Very Elderly Trial
Medical condition: Type 2 Diabetes Mellitus
Disease: Version SOC Term Classification Code Term Level
Population Age: Elderly Gender: Male, Female
Trial protocol: GB (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2004-001770-40 Sponsor Protocol Number: 11546 Start Date: 2005-06-03
Sponsor Name: Bayer HealthCare AG
Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma.
Medical condition: advanced hepatocellular carcinoma
Disease: Version SOC Term Classification Code Term Level
7.1 10049010 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results
EudraCT Number: 2005-001043-32 Sponsor Protocol Number: MEN001 Start Date: 2005-06-03
Sponsor Name: University of Dundee
Full Title: A PROOF OF CONCEPT STUDY TO EVALUATE THE DOSE RESPONSE FOR THE SYSTEMIC BENEFIT RISK RATIO OF INHALED FLUTICASONE PROPIONATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Medical condition: Chronic Obstructive Pulmonary Disease
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results
EudraCT Number: 2004-004387-72 Sponsor Protocol Number: 291-411 Start Date: 2005-06-03
Sponsor Name: PDL BioPharma, Inc.
Full Title: A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease.
Medical condition: Crohn’s disease (CD) in patients with at least one perianal fistula.
Disease: Version SOC Term Classification Code Term Level
7.1 10011401 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) AT (Completed)
Trial results: (No results available)
EudraCT Number: 2005-001007-18 Sponsor Protocol Number: 2989 Start Date: 2005-06-03
Sponsor Name: Royal Victoria Infirmary
Full Title: Reversal of warfarin anticoagulation with oral vitamin K: towards a better management of over-anticoagulation
Medical condition: Patients with thromboembolic disorders are anticogulated with warfarin. However excessive over-anticoagulation can increase the patient risk of bleeding. Oral vitamin K is routinely used for revers...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results
EudraCT Number: 2004-004388-31 Sponsor Protocol Number: 291-412 Start Date: 2005-06-03
Sponsor Name: PDL BioPharma, Inc
Full Title: A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease
Medical condition: Moderate-to-severe inflammatory, nonstricturing, nonpenetrating Crohn’s disease (CD).
Disease: Version SOC Term Classification Code Term Level
7.1 10011401 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)
EudraCT Number: 2004-000622-67 Sponsor Protocol Number: 3147K2-101WW Start Date: 2005-06-03
Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy.
Medical condition: Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results
EudraCT Number: 2005-000558-60 Sponsor Protocol Number: PX104.1.7-202 Start Date: 2005-06-02
Sponsor Name: Pharmexa A/S
Full Title: A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancer
Medical condition: Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: HU (Ongoing)
Trial results: (No results available)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe